within Pharmacolibrary.Drugs.ATC.M;

model M01CB01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.3333333333333334e-05,
    adminDuration  = 600,
    adminMass      = 50 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.00031,
    k12             = 1.0,
    k21             = 1.0
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01CB01</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Sodium aurothiomalate is a gold-containing compound formerly used primarily in the treatment of rheumatoid arthritis as a disease-modifying antirheumatic drug (DMARD). It is administered parenterally, usually by intramuscular injection. Its use has largely declined due to safety concerns and the availability of more effective agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with rheumatoid arthritis. Values are typically reported in clinical studies from patients treated with intramuscular sodium aurothiomalate.</p><h4>References</h4><ol><li><p>Massarella, JW, et al., &amp; Yakatan, GJ (1984). The pharmacokinetics of intramuscular gold sodium thiomalate in normal volunteers. <i>Biopharmaceutics &amp; drug disposition</i> 5(2) 101–107. DOI:<a href=&quot;https://doi.org/10.1002/bdd.2510050203&quot;>10.1002/bdd.2510050203</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6430362/&quot;>https://pubmed.ncbi.nlm.nih.gov/6430362</a></p></li><li><p>Bennett, PN, et al., &amp; Taylor, A (1990). Use of sodium aurothiomalate during lactation. <i>British journal of clinical pharmacology</i> 29(6) 777–779. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.1990.tb03703.x&quot;>10.1111/j.1365-2125.1990.tb03703.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2116162/&quot;>https://pubmed.ncbi.nlm.nih.gov/2116162</a></p></li><li><p>Furst, DE (1983). Mechanism of action, pharmacology, clinical efficacy and side effects of auranofin. An orally administered organic gold compound for the treatment of rheumatoid arthritis. <i>Pharmacotherapy</i> 3(5) 284–298. DOI:<a href=&quot;https://doi.org/10.1002/j.1875-9114.1983.tb03277.x&quot;>10.1002/j.1875-9114.1983.tb03277.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6417628/&quot;>https://pubmed.ncbi.nlm.nih.gov/6417628</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01CB01;
